RISK WATCHSeekingAlpha • 2d ago
Ardelyx: Revisiting The Thesis 2 Years On, I'm Surprised At Lack Of ProgressArdelyx faces slowing revenue growth, Medicare reimbursement risks, and 2026 guidance cuts. Click here for this detailed ARDX update.
Why ARDX Stock dropped -2.26% Today — RQD Quant Desk Flash
$3.03 -2.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.01
Ardelyx Inc. (ARDX) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $772.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ARDX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ARDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Ardelyx Inc. (NASDAQ: ARDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.03 (-2.26% 1D, market cap $772.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARDX ranks #953 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ARDX compare to COLL and HELP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARDX carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 90.3%, and ROIC of -32.7%. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and HELP (Helus Pharma Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ARDX?
▼
Per ARDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001437402), Ardelyx Inc. generated $407.3M in revenue (+22.1% YoY), -$62.0M in net income, and -$44.0M in free cash flow against $501.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.01 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARDX)Realized 20D OHLCV Swing Band: ±8.6%
Deterministic 5-Pillar Attribution (24/100 Composite)
🔍 WHY ARDX SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (33% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 90.3% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.23-4.3% Next Q
32
Q2 (-2Q)Grade E$3.09-2.9% Next Q
29
Q3 (-1Q)Grade E$3.00+1% Next Q
27
CurrentGrade E$3.03-10.9% Hist 90D α
24
Trajectory: E (32) → E (24)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ARDX Turnaround Squeeze
While ARDX currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.41) and Max Pain ($3.18) forces dealer call-delta covering toward $8.82.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ARDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ARDX Stock dropped -2.26% Today — RQD Quant Desk Flash
Ardelyx Inc. (ARDX) dropped -2.26% to $3.03, trading at 2% of its 52-week range ($2.95 – $8.4). Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.95 – $8.4) with RSI-14 at 42.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.6% around $3.03 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 90.3% gross margin and $0 annual free cash flow.
Live ARDX Headlines & Catalysts
MARKET WIREYahoo • 9d ago
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersReal-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity a
MARKET WIREBenzinga • 9d ago
Ardelyx Reports Real-World Phosphate Reductions With XPHOZAH Across Phosphate Binder Groups In Dialysis Patients, Presented At The ASN Kidney Week 2026Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluatedAdditional data highlighted the challenges of managing hyperphosphatemia and the morbidity
MARKET WIREYahoo • 12d ago
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARDX)
- ✓Walkthrough of ARDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ARDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.49%🛡️ HOLDING TREND SUPPORT
2026-11-02O $3.10H $3.10L $3.03C $3.03VOL 2.55M
SUP: $2.67SMA50: $3.41SMA200: $5.32
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ARDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +22.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ARDX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ARDX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARDX)
Health Care Rank #953 of 1016
⚔️ COLL vs ARDX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ARDX vs. COLL, HELP, ANNX, AVBP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Ardelyx Inc. (ARDX) ranks #953 by composite RQD confidence (24/100, grade E) and #391 by equity capitalization ($772.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ARDX at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARDX
ACTIVE
Ardelyx Inc. | E | 24/100 | — | 90.3% | -32.7% | -2.26% | $772.5M | Benchmark Subject |
| COLL Collegium Pharmaceutical Inc. | C- | 59/100 | 12.4x | 59.3% | 85.0% | -0.96% | $782.3M | /coll-vs-ardx → |
| HELP Helus Pharma Inc. | D+ | 54/100 | — | — | — | -1.07% | $782.5M | /help-vs-ardx → |
| ANNX Annexon Inc. | E | 30/100 | — | — | -35.0% | +1.00% | $760.2M | /annx-vs-ardx → |
| AVBP ArriVent BioPharma Inc. | E | 29/100 | — | — | -35.0% | -6.77% | $786.5M | /avbp-vs-ardx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001437402In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ardelyx Inc. (ARDX) reported GAAP revenue of $407.3M (+22.1% vs. FY2024 revenue of $333.6M , and +227.3% cumulative change since FY2023) , GAAP net income of -$62.0M, operating cash flow of -$42.5M, and free cash flow of -$44.0M (+4.0% YoY). On the balance sheet, ARDX closed FY2025 with $501.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $407.3M | -$62.0M | -$42.5M | -$44.0M | $501.6M | — |
| FY2024 (FY) | 2024-12-31 | $333.6M | -$39.0M | -$44.8M | -$45.8M | $435.8M | — |
| FY2023 (FY) | 2023-12-31 | $124.5M | -$66.0M | -$89.7M | -$89.7M | — | — |
3. ARDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ARDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Ardelyx Inc. (NASDAQ: ARDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.03 (-2.26% 1D, market cap $772.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARDX ranks #953 in composite RQD confidence.
How does ARDX compare to COLL and HELP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARDX carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 90.3%, and ROIC of -32.7%. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and HELP (Helus Pharma Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ARDX?
Per ARDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001437402), Ardelyx Inc. generated $407.3M in revenue (+22.1% YoY), -$62.0M in net income, and -$44.0M in free cash flow against $501.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ARDX trading relative to its 50-day, 200-day, and 52-week technical levels?
ARDX last traded at $3.03 (-2.26% on volume of 3,625,905 shares), positioning the stock -11.14% below its 50-day simple moving average ($3.41) and -43.05% below its 200-day simple moving average ($5.32). Across its 52-week range of $2.95 to $8.40, ARDX sits at the 1.5% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($2.77 to $3.29).
ARDX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ARDX stock moving today?
Why ARDX Stock dropped -2.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.